Healthcare / Drug Manufacturers - Specialty & GenericIstanbul
$86.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 22%
FCF escenarios
weak_data · normalized FCF $2.1B · quality 49.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
61/100
B
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$58.9B
P/E
28.2x
↑EV/EBITDA
12.0x
↓ROE
3.4%
↑Gross Margin
33.4%
↓Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+41.7%
FCF CAGR
—
FCF margin
11.3%
FCF / Net income
0.53x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.87B · net income $2.09B · FCF $1.11B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.87B | $9.87B | $11.48B | $9.36B | $3.47B |
| Net Income | $2.09B | $2.09B | $1.34B | $3.96B | $2.98B |
| EBITDA | $4.80B | $4.80B | $4.12B | $6.42B | $3.79B |
| EPS | 3.05 | 3.05 | 1.96 | 5.77 | 4.35 |
| Gross Margin | 33.4% | 33.4% | 34.0% | 33.8% | 31.1% |
| Operating Margin | -9.3% | -9.3% | -1.2% | 3.8% | 2.1% |
| Net Margin | 21.2% | 21.2% | 11.7% | 42.3% | 86.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.07 | 0.09 | 0.10 |
| Current Ratio | 1.73 | 1.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.11B | $1.11B | $2.11B | $2.21B | $-1.24B |
| Returns | |||||
| ROE | 3.4% | 3.4% | 2.3% | 7.9% | 9.5% |
| Valuation | |||||
| P/E | 28.20 | 28.20 | 24.63 | 7.69 | 7.19 |
| EV/EBITDA | 12.00 | 12.00 | 8.29 | 4.98 | 6.26 |
| P/B | 0.97 | 0.97 | 0.56 | 0.60 | 0.69 |
| Growth & Yield | |||||
| Revenue Growth | -14.0% | -14.0% | 22.7% | 169.9% | — |
| EPS Growth | 55.6% | 55.6% | -66.0% | 32.5% | — |
| Dividend Yield | 2.0% | 2.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
35.8%
EPS terminal req.
$7.63
Spread vs growth
19.9%
5Y implied EPS CAGR
24.8%
EPS terminal req.
$9.23
Spread vs growth
30.8%
10Y implied EPS CAGR
17.2%
EPS terminal req.
$14.87
Spread vs growth
38.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+94.8%
Start / end P/E
23.5x → 29.1x
EPS bridge
1.96 → 3.05
Residual
+13.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.